GlassScriptPhysician profile
Hannah M Helm
NPI 1073056248
$2,801.03
in general payments reported to CMS, 2019-2025
25 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $218 · 2022: $938 · 2023: $600 · 2024: $923 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,645.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $723.58 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.33 | 2021-2024 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $246.36 | 2021-2024 | Stelara, Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $245.77 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $225.82 | 2021-2024 | Entyvio, Gattex |
| Gilead Sciences, INC. | $211.92 | 2021-2024 | |
| Madrigal Pharmaceuticals | $153.40 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $109.60 | 2022-2024 | Zeposia |
| Genzyme Corporation | $107.82 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $70.39 | 2022-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $63.18 | 2021-2023 | |
| Lilly USA, LLC | $57.18 | 2024 | Omvoh |
| Braintree Laboratories, INC. | $48.47 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $41.62 | 2024 | Iqirvo |
| Aimmune Therapeutics, INC. | $33.70 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $30.28 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $29.62 | 2024 | Dupixent |
| Pfizer INC. | $23.94 | 2022 | |
| Shield Therapeutics INC | $20.29 | 2022 | |
| Ferring Pharmaceuticals INC. | $18.95 | 2023 | Rebyota |
| Ardelyx, INC. | $18.36 | 2022 | |
| Intercept Pharmaceuticals, INC. | $17.79 | 2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $16.86 | 2024 | Voquezna |
| Qol Medical, LLC | $16.25 | 2021 | |
| Exact Sciences Corporation | $14.55 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Helm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.